Published in Br J Clin Pharmacol on October 28, 2015
The Effect of Structured Education to Patients Receiving Oral Agents for Cancer Treatment on Medication Adherence and Self-efficacy. Asia Pac J Oncol Nurs (2017) 0.75
Oral Agents in Cancer Treatment: Meeting the Patients' Needs to Ensure Medication Adherence. Asia Pac J Oncol Nurs (2017) 0.75
Adherence to medication. N Engl J Med (2005) 39.77
Targeted cancer therapy. Nature (2004) 7.81
Medication compliance and persistence: terminology and definitions. Value Health (2008) 7.58
How often is medication taken as prescribed? A novel assessment technique. JAMA (1989) 5.98
Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol (2003) 4.95
Cost-related medication nonadherence and spending on basic needs following implementation of Medicare Part D. JAMA (2008) 4.74
Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol (2010) 4.43
Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol (1997) 4.43
Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol (2010) 4.21
Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin (2009) 4.18
Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst (2002) 4.16
Interventions to enhance medication adherence. Cochrane Database Syst Rev (2005) 4.08
Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol (2008) 4.06
NCCN Task Force Report: Oral chemotherapy. J Natl Compr Canc Netw (2008) 3.82
Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol (2009) 3.63
Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood (2009) 3.47
Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol (2007) 3.42
Early discontinuation of tamoxifen: a lesson for oncologists. Cancer (2007) 3.12
Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor--positive breast cancer. J Clin Oncol (2004) 3.03
Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat (2006) 2.55
Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. J Clin Oncol (1993) 2.43
Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J Clin Oncol (2001) 2.36
Oral chemotherapy safety practices at US cancer centres: questionnaire survey. BMJ (2007) 2.26
Expanding the roles of outpatient pharmacists: effects on health services utilisation, costs, and patient outcomes. Cochrane Database Syst Rev (2000) 2.12
Predictors of medication adherence in the elderly. Clin Ther (1998) 1.90
Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics (2007) 1.87
Intentional and non-intentional non-adherence to medication amongst breast cancer patients. Eur J Cancer (2006) 1.66
Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood (2011) 1.63
Review: side effects of approved molecular targeted therapies in solid cancers. Oncologist (2007) 1.61
Adherence beliefs among breast cancer patients taking tamoxifen. Patient Educ Couns (2005) 1.61
2013 updated American Society of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards including standards for the safe administration and management of oral chemotherapy. J Oncol Pract (2013) 1.58
Adherence and patients' experiences with the use of oral anticancer agents. Acta Oncol (2013) 1.56
Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia. Curr Med Res Opin (2012) 1.53
Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104. J Clin Oncol (2010) 1.44
Oral cancer treatment: developments in chemotherapy and beyond. Br J Cancer (2002) 1.44
Patient noncompliance with self-administered chemotherapy. Cancer (1990) 1.40
Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer. Breast Cancer Res Treat (2010) 1.40
Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions. J Oncol Pract (2011) 1.38
Patient education: the cornerstone of successful oral chemotherapy treatment. Clin J Oncol Nurs (2004) 1.34
A changing paradigm for cancer treatment: the advent of new oral chemotherapy agents. Clin J Oncol Nurs (2004) 1.32
Unfilled prescriptions of medicare beneficiaries: prevalence, reasons, and types of medicines prescribed. J Manag Care Pharm (2008) 1.30
Five-year patterns of adjuvant hormonal therapy use, persistence, and adherence among insured women with early-stage breast cancer. Breast Cancer Res Treat (2011) 1.21
Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer. Breast Cancer Res Treat (2009) 1.19
Anticancer oral therapy: emerging related issues. Cancer Treat Rev (2010) 1.17
Determinants and associated factors influencing medication adherence and persistence to oral anticancer drugs: a systematic review. Cancer Treat Rev (2013) 1.15
Determinants of compliance with medication in patients with rheumatoid arthritis: the importance of self-efficacy expectations. Patient Educ Couns (1999) 1.15
Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia. Am J Hematol (2011) 1.12
Tamoxifen non-compliance: does it matter? Lancet Oncol (2002) 1.12
What are validated self-report adherence scales really measuring?: a systematic review. Br J Clin Pharmacol (2014) 1.11
Safe administration of oral chemotherapy. Clin J Oncol Nurs (2003) 1.10
Effect of personal and cultural beliefs on medication adherence in the elderly. Drugs Aging (2006) 1.09
Capecitabine non-adherence: exploration of magnitude, nature and contributing factors. J Oncol Pharm Pract (2012) 1.08
Answering patients' needs: oral alternatives to intravenous therapy. Oncologist (2001) 1.06
Self-reported compliance with capecitabine: findings from a prospective cohort analysis. Oncology (2011) 1.02
Adherence to adjuvant hormonal therapy and its relationship to breast cancer recurrence and survival among low-income women. Am J Clin Oncol (2013) 1.02
Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients. Curr Med Res Opin (2010) 1.01
Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia. Curr Med Res Opin (2010) 0.99
Safety considerations and safe handling of oral chemotherapy agents. Clin J Oncol Nurs (2004) 0.99
Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: a population-based study. Breast Cancer Res Treat (2012) 0.97
Patient compliance with prolonged low-dose oral etoposide for small cell lung cancer. Br J Cancer (1993) 0.94
A comparison of patient adherence and preference of packaging method for oral anticancer agents using conventional pill bottles versus daily pill boxes. Eur J Cancer Care (Engl) (2007) 0.94
Patient compliance with oral chemotherapy as assessed by a novel electronic technique. J Clin Oncol (1992) 0.93
Patient adherence to pharmacotherapy: the importance of effective communication. Formulary (1995) 0.93
Feasibility of a novel weekday-on/weekend-off oral UFT schedule as postoperative adjuvant chemotherapy for colorectal cancer. UFT Compliance Study Group, Kanagawa, Japan. Cancer Chemother Pharmacol (2000) 0.93
Good adherence to imatinib therapy among patients with chronic myeloid leukemia--a single-center observational study. Ann Hematol (2011) 0.92
Safe practices and financial considerations in using oral chemotherapeutic agents. Am J Health Syst Pharm (2007) 0.88
Adherence with oral oncologic treatment in cancer patients: interest of an adherence score of all dosing errors. Oncology (2012) 0.87
Oral anticancer agent medication adherence by outpatients. Oncol Lett (2014) 0.87
Target and reality of adjuvant endocrine therapy in postmenopausal patients with invasive breast cancer. Br J Cancer (2008) 0.86
Patient compliance with prolonged oral altretamine treatment in relapsed ovarian cancer. Eur J Gynaecol Oncol (1996) 0.86
Oral anticancer drugs in the elderly: an overview. Drugs Aging (2007) 0.85
Adherence to tyrosine kinase inhibitor therapy for chronic myeloid leukemia: a Brazilian single-center cohort. Acta Haematol (2013) 0.85
Adherence influencing factors in patients taking oral anticancer agents: a systematic review. Cancer Epidemiol (2014) 0.85
Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: a Cancer and Leukemia Group B study. Cancer Chemother Pharmacol (2005) 0.84
Cost-effectiveness analyses of targeted oral anti-cancer drugs: a systematic review. Pharmacoeconomics (2014) 0.84
Adherence, compliance and persistence to oral antineoplastic therapy: a review focused on chemotherapeutic and biologic agents. Expert Opin Drug Saf (2011) 0.84
Managing oral chemotherapy: the healthcare practitioner's role. Am J Health Syst Pharm (2007) 0.84
Adherence, exposure and patients' experiences with the use of erlotinib in non-small cell lung cancer. J Cancer Res Clin Oncol (2015) 0.83
Nonadherence to imatinib treatment in patients with gastrointestinal stromal tumors: the ADAGIO study. Anticancer Res (2011) 0.83
Persistence, adherence, and toxicity with oral CMF in older women with early-stage breast cancer (Adherence Companion Study 60104 for CALGB 49907). Ann Oncol (2012) 0.83
Assessing adherence to oral chemotherapy using different measurement methods: Lessons learned from capecitabine. J Oncol Pharm Pract (2013) 0.83
Measurement of drug compliance by continuous electronic monitoring: a pilot study in elderly patients discharged from hospital. J Am Geriatr Soc (1992) 0.83
Perceptions and experiences of patients receiving oral chemotherapy. Clin J Oncol Nurs (2010) 0.82
Self-administration of medicine and older people. Nurs Stand (2002) 0.82
A retrospective analysis of therapy adherence in imatinib resistant or intolerant patients with chronic myeloid leukemia receiving nilotinib or dasatinib in a real-world setting. Curr Med Res Opin (2012) 0.82
Oral cancer chemotherapy adherence and adherence assessment tools: a report from North Central Cancer Group Trial N0747 and a systematic review of the literature. J Cancer Educ (2013) 0.81
Are patients on oral chemotherapy in your practice setting safe? Clin J Oncol Nurs (2010) 0.81
Factors influencing oral adherence: qualitative metasummary and triangulation with quantitative evidence. Clin J Oncol Nurs (2015) 0.80
Medication adherence among adults prescribed imatinib, dasatinib, or nilotinib for the treatment of chronic myeloid leukemia. J Oncol Pharm Pract (2014) 0.78
Identifying strategies to optimize care with oral cancer therapy. Clin J Oncol Nurs (2013) 0.76
Adherence and patients' attitudes to oral anticancer drugs: a prospective series of 201 patients focusing on targeted therapies. Oncology (2014) 0.76
Assessment and measurement of medication adherence: oral agents for cancer. Clin J Oncol Nurs (2015) 0.76
Anti-androgen prescribing patterns, patient treatment adherence and influencing factors; results from the nationwide PCBaSe Sweden. Eur J Clin Pharmacol (2012) 0.76
Re: Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst (2002) 0.75